DARA BioSciences has initiated a Phase Ib clinical study of DB959, its peroxisome proliferator-activated receptor delta / gamma agonist for the treatment of type 2 diabetes.
DB959 affects certain nuclear receptors that regulate the genes involved in controlling blood sugar levels and certain lipids.
The study is designed to determine the safety and pharmacokinetics of multiple ascending oral doses of DB959 in men and women. Results are expected to be published during the third quarter of 2011.
The results of a Phase Ia study demonstrated a promising safety profile and pharmacokinetic profile that supports a once-a-day oral dose.
In addition, preclinical studies revealed that DB959 controlled glucose while raising HDL and the HDL:LDL ratio, and lowering triglycerides.